265 related articles for article (PubMed ID: 16271898)
1. A rational approach to evidence gaps in the management of osteoporosis.
Rosen CJ; Brown SA
Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
[TBL] [Abstract][Full Text] [Related]
4. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
5. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
6. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
7. [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].
Iwamoto J
Clin Calcium; 2010 Mar; 20(3):396-407. PubMed ID: 20190370
[TBL] [Abstract][Full Text] [Related]
8. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
[TBL] [Abstract][Full Text] [Related]
9. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
10. Prevention of osteoporotic fractures in the elderly.
Wilkins CH; Birge SJ
Am J Med; 2005 Nov; 118(11):1190-5. PubMed ID: 16271899
[TBL] [Abstract][Full Text] [Related]
11. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
Soen S
Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
[TBL] [Abstract][Full Text] [Related]
12. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
[TBL] [Abstract][Full Text] [Related]
13. [Role of pharmaceutical intervention in the treatment of osteoporosis and prevention of fracture].
Nakamura T
Nihon Rinsho; 2009 May; 67(5):903-8. PubMed ID: 19432107
[TBL] [Abstract][Full Text] [Related]
14. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
15. [The successful development of bisphosphonates in the therapy of osteoporosis].
Fassbender WJ; Stumpf UC; Kurth A
Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
[TBL] [Abstract][Full Text] [Related]
16. Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results.
Watts NB
J Reprod Med; 2002 Jan; 47(1 Suppl):82-92. PubMed ID: 11829081
[TBL] [Abstract][Full Text] [Related]
17. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
18. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
[TBL] [Abstract][Full Text] [Related]
19. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
[No Abstract] [Full Text] [Related]
20. [Progress in the treatment of osteoporosis].
Sugimoto T
Rinsho Byori; 2008 Oct; 56(10):887-93. PubMed ID: 19068785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
